Medtech Trends 2026: Strategic Implications for the Asia-Pacific Region

Executive Summary

The medical technology (medtech) industry in the Asia-Pacific region is entering a period of accelerated change. Structural forces across pricing, care delivery, supply chains, clinical pathways, and enabling technologies are reshaping how companies compete and where growth will occur. This analysis, based on Clarivate's Medtech Trends to Watch 2026, highlights five trends that will have outsized consequences for the region: China's volume-based procurement (VBP) expansion, the shift to outpatient and ambulatory care, global supply chain pressures, the impact of GLP-1 therapies, and the emergence of platform-based competition. Together, these trends demand strategic reinvention from multinational corporations and local innovators alike.

Introduction

The Asia-Pacific region is a critical engine of global medtech growth, accounting for a significant share of worldwide demand and manufacturing. Yet the forces reshaping the industry are multi-faceted and often originate outside the region. From China's evolving procurement policies to the global recalibration of supply chains, medtech companies operating in Asia-Pacific must navigate a complex and dynamic environment. The five trends identified in Clarivate's 2026 outlook are not isolated developments; they are interconnected shifts that will redefine market economics, clinical practice, and competitive advantage across the region.

Main Analysis

1. China's VBP Expansion Reshapes Market Economics

Mainland China's latest national volume-based procurement (VBP) round is one of the most consequential shifts in global medtech pricing. What began as a mechanism to expand patient access and control device costs has evolved into a powerful market-structuring tool. The newest rules employ more sophisticated anchor-price logic, deeper price compression, and allocation systems that favor domestic manufacturers.

For multinational medtech companies, VBP is no longer a localized issue. It influences pricing expectations, volume dynamics, and competitive positioning well beyond China's borders. In the Asia-Pacific context, this means companies must recalibrate their portfolio strategies and cost structures to remain viable in one of the world's largest markets. At the same time, VBP is accelerating domestic innovation, as Chinese manufacturers gain scale and invest in R&D, potentially intensifying competition in other emerging markets across Southeast Asia.

2. Outpatient and Ambulatory Settings Gain Traction

The migration of procedures from hospitals to outpatient settings is a defining medtech trend. While the U.S. Centers for Medicare & Medicaid Services (CMS) has been a key driver, similar shifts are visible across Asia-Pacific healthcare systems, where cost pressures and patient preferences are pushing less complex procedures to ambulatory surgical centers (ASCs) and day-surgery units.

This trend matters for medtech companies because it changes where and how devices are used. Product designs must accommodate different care settings, and commercial models must address the economic realities of lower-cost environments. In Asia-Pacific, where hospital infrastructure is expanding unevenly, the outpatient shift could accelerate as countries like Japan, South Korea, and Singapore modernize their healthcare delivery systems.

3. Supply Chain Pressures Reshape Manufacturing Strategy

Global trade and supply chain resilience have become strategic imperatives for the medtech industry. Tariff exposure, geopolitical tensions, and fluctuating material costs are challenging assumptions about where and how devices should be produced. In response, companies are diversifying sourcing, re-evaluating manufacturing footprints, and investing in flexible multi-region production.

Asia-Pacific is at the heart of this transformation. The region is both a major manufacturing base and a growing consumer market. Countries like Vietnam, Thailand, and Malaysia are emerging as alternative hubs as companies seek to reduce reliance on concentrated supply chains. Larger manufacturers are using scale and technology investment to weather volatility, potentially widening the gap between market leaders and smaller players.

4. GLP-1 Therapies Shift Patient Behavior and Care Pathways

The rapid adoption of glucagon-like peptide-1 (GLP-1) receptor agonists for weight management is altering clinical pathways across multiple therapy areas. While bariatric surgery remains the most effective intervention for substantial weight loss, the popularity of GLP-1s is changing referral patterns and influencing demand for related medical devices.

In the Asia-Pacific, rising obesity rates and increased focus on metabolic health make this trend particularly relevant. The downstream effects on diabetes care, sleep apnea monitoring, and cardiovascular devices are only beginning to surface. Medtech companies must track these shifts and adapt their portfolios to address evolving patient needs.

5. Enabling Technologies Drive Platform-Based Competition

Across medtech, enabling technologies such as robotics, imaging, navigation, and digital workflow software are reshaping competition. These technologies are no longer peripheral tools; they are central to integrated ecosystems that support clinical planning, surgical execution, and postoperative care.

Companies are investing in platform architectures that anchor entire service lines and strengthen customer relationships. In Asia-Pacific, where healthcare digitalization is advancing rapidly, platforms that combine hardware, software, and data analytics will be key to differentiation. Emerging open-platform systems are also creating new competitive dynamics, allowing hospitals to integrate best-in-class components rather than being locked into a single vendor.

Regional Impact

These trends collectively reshape the Asia-Pacific medical technology market in several ways:

• Economic growth: VBP-related price compression in China could pressure revenue growth for incumbents but create opportunities for cost-competitive innovators.
• Business competitiveness: Supply chain diversification is altering the region's manufacturing map, with implications for countries seeking to attract investment.
• Trade integration: As companies adapt to tariff pressures, regional trade agreements like RCEP may play a larger role in facilitating cross-border supply chains.
• Technology adoption: Platform-based competition and digital workflows are accelerating the adoption of AI and data analytics in healthcare.
• Policy impact: Governments across the region are likely to revisit procurement policies and industrial strategies to balance access, innovation, and local industry development.

Strategic Insights

For medtech executives in the Asia-Pacific, the key strategic takeaways are:

• Localize portfolio strategy: Understand the nuances of VBP in China and similar procurement mechanisms elsewhere. Consider developing cost-effective product variants for price-sensitive markets.
• Diversify manufacturing: Build resilient supply chains with multi-region footprints to mitigate tariff and geopolitical risks.
• Adapt to shifting care settings: Design products for outpatient and ambulatory environments, and develop value propositions that resonate with providers in these settings.
• Monitor metabolic health trends: GLP-1 adoption will have ripple effects across many device categories; proactive portfolio adjustments are needed.
• Invest in platform ecosystems: Integrate enabling technologies to create stickier customer relationships and unlock new data-driven services.

Future Outlook (2026–2030)

Over the next three to five years, the Asia-Pacific medtech landscape will likely see:

• Continued evolution of VBP: China will refine its procurement mechanisms, putting further pressure on pricing and accelerating domestic substitution.
• Rise of next-tier manufacturing hubs: Countries like Vietnam and India will gain prominence as companies diversify beyond China.
• Digital health integration: Platform-based medtech will converge with telemedicine and AI diagnostics, creating new care models.
• Growing importance of metabolic disease management: GLP-1s will reshape care pathways, and medtech companies will respond with integrated solutions.
• Regional cooperation: Trade agreements and cross-border collaboration will facilitate the flow of devices and talent, strengthening the region's position in global medtech.

Conclusion

The medtech industry in the Asia-Pacific is at an inflection point. The five trends outlined in this analysis are not transient; they will define competitive dynamics, market access, and innovation trajectories for the rest of the decade. Companies that act strategically—by recalibrating their pricing models, diversifying supply chains, embracing platform ecosystems, and responding to shifts in care delivery—will be best positioned to thrive. Policymakers also have a role to play in fostering an environment that balances access, innovation, and sustainable industry development.

Sources

• Clarivate. "5 medtech trends to watch in 2026." https://clarivate.com/life-sciences-healthcare/blog/5-medtech-trends-to-watch-in-2026